Chronic Obstructive Pulmonary Disease (COPD)

    Not Recruiting
  • sponsor
    Verona Pharma
Updated on 19 January 2022


The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).


  • Condition: Chronic Obstructive Pulmonary Disease (COPD)
  • Drug: Ensifentrine
  • Clinical Trial Identifier: NCT04542057
  • Sponsor: Verona Pharma

Condition chronic obstructive pulmonary disease, COPD, chronic obstructive pulmonary disease (copd)
Clinical Study IdentifierTX279553
SponsorVerona Pharma
Last Modified on19 January 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note